Neticonazole

Fungal infection is a highly prevalent infectious disease globally, among which superficial skin fungal infections account for more than 60%. The patient group covers all age groups, the disease is prone to recurrent attacks, and the problem of drug resistance has gradually become prominent. Neticonazole is an imidazole antifungal API. It inhibits the biosynthesis of ergosterol in the fungal cell membrane to destroy the structural integrity of the cell membrane, and at the same time inhibits the activities of fungal oxidase and peroxidase to promote the accumulation of intracellular peroxides, ultimately realizing fungal apoptosis. This drug has broad-spectrum antibacterial activity against a variety of pathogenic fungi such as Trichophyton rubrum, Candida, and Malassezia. It is clinically mainly used for the local treatment of tinea corporis, tinea cruris, tinea manus and pedis, tinea versicolor and cutaneous candidiasis, and can also be used for the adjuvant intervention of vaginal Candida infection.

The global market size of topical antifungal drugs exceeded US$9.8 billion in 2023, among which imidazole drugs account for 42% of the topical antifungal drug market. As a new generation of topical imidazole drugs, neticonazole has a compound annual growth rate of 7.2% in the past three years due to its lower skin irritation and longer duration of action, which is higher than the average growth rate of similar drugs ketoconazole and miconazole. At present, the global supply of neticonazole API is mainly concentrated in China and India, accounting for 81% of the global production capacity in total. After the implementation of domestic centralized procurement, the terminal accessibility of topical antifungal preparations has been significantly improved, driving the continuous rise of market demand for upstream neticonazole API, and the domestic demand in 2024 increased by more than 18% year-on-year.

The original research enterprise of neticonazole is Kotobuki Pharmaceutical Co., Ltd. of Japan, and the original research brand name is "ネリゾナ" (Nerizona). Its core compound patent expired in Japan in 2008, and there are no unexpired core compound patents in other major markets. The main dosage form of the original research marketed product is topical cream, with the specification of 10g:0.1g (1% concentration). This original research preparation has been included in the list of pharmaceutical products of the Ministry of Health, Labour and Welfare of Japan, and has not been included in the Chinese *Catalogue of Reference Preparations for Chemical Drugs* for the time being. Up to now, there are no approved neticonazole preparation products marketed in China, and the API registration platform of the Center for Drug Evaluation (CDE) of the National Medical Products Administration has not yet announced valid neticonazole API registration numbers. (Data as of June 2025, please refer to the official CDE website for the latest information)

CATO can provide a full set of neticonazole impurity reference standards. Most of the products are in stock. Spot orders placed before 16:00 can be shipped on the same day. All products meet the compliance requirements of multiple regulatory systems such as Chinese Pharmacopoeia and FDA, and can fully meet the use needs of various links such as API research and development, quality research, and impurity control.